BRAINSTORM CELL THERAPEUTICS INC. Financials Brainstorm Cell Therapeutics Inc. Deutsche Boerse AG
Equities
GHDN
US10501E2019
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.4655 EUR | +6.89% |
|
+9.53% | +102.39% |
| 17/04 | Brainstorm Cell Therapeutics Inc. Announces Step Down of Stacy Lindborg as Co-CEO, Effective as of May 9, 2024 | CI |
| 17/04 | Brainstorm Cell Therapeutics Inc. Announces Management Changes | CI |
Valuation
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Capitalization 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 35.26 | - | - |
| Enterprise Value (EV) 1 | 96.76 | 142.8 | 145.1 | 59.93 | 13.37 | 35.26 | 35.26 | 35.26 |
| P/E ratio | -4.04 x | -4.23 x | -5.88 x | -2.48 x | -0.68 x | -1.84 x | -1.38 x | -1.24 x |
| Yield | - | - | - | - | - | - | - | - |
| Capitalization / Revenue | - | - | - | - | - | - | - | - |
| EV / Revenue | - | - | - | - | - | - | - | - |
| EV / EBITDA | - | - | - | - | - | - | - | - |
| EV / FCF | - | - | - | - | - | - | - | - |
| FCF Yield | - | - | - | - | - | - | - | - |
| Price to Book | - | - | - | - | - | - | - | - |
| Nbr of stocks (in thousands) | 22,606 | 31,568 | 36,278 | 36,542 | 48,982 | 68,342 | - | - |
| Reference price 2 | 4.280 | 4.525 | 4.000 | 1.640 | 0.2730 | 0.5160 | 0.5160 | 0.5160 |
| Announcement Date | 18/02/20 | 04/02/21 | 28/03/22 | 30/03/23 | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Annual data)
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - |
| EBIT 1 | -23 | -31.68 | -24.54 | -24.82 | -21.44 | -21.9 | -27.43 | -31.1 |
| Operating Margin | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
| Net income 1 | -23.25 | -31.81 | -24.46 | -24.28 | -17.19 | -21.9 | -27.43 | -31.1 |
| Net margin | - | - | - | - | - | - | - | - |
| EPS 2 | -1.060 | -1.070 | -0.6800 | -0.6600 | -0.4000 | -0.2800 | -0.3750 | -0.4150 |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| FCF margin | - | - | - | - | - | - | - | - |
| FCF Conversion (EBITDA) | - | - | - | - | - | - | - | - |
| FCF Conversion (Net income) | - | - | - | - | - | - | - | - |
| Dividend per Share | - | - | - | - | - | - | - | - |
| Announcement Date | 18/02/20 | 04/02/21 | 28/03/22 | 30/03/23 | 01/04/24 | - | - | - |
1USD in Million2USD
Estimates
Income Statement Evolution (Quarterly data)
| Fiscal Period: December | 2021 Q4 | 2022 Q1 | 2022 Q2 | 2022 Q3 | 2022 Q4 | 2023 Q1 | 2023 Q2 | 2023 Q3 | 2023 Q4 | 2024 Q1 | 2024 Q2 | 2024 Q3 | 2024 Q4 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net sales 1 | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EBIT 1 | -6.212 | -5.475 | -7.591 | -6.841 | -4.915 | -5.151 | -5.449 | -6.035 | -4.804 | -2.474 | -5.2 | -5.8 | -6.4 |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Earnings before Tax (EBT) 1 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -3.401 | -5.2 | -5.8 | -6.4 |
| Net income 1 | -6.19 | -5.36 | -7.041 | -6.858 | -5.018 | -5.059 | -5.329 | -1.226 | -5.578 | -3.401 | -5.2 | -5.8 | -6.4 |
| Net margin | - | - | - | - | - | - | - | - | - | - | - | - | - |
| EPS 2 | -0.1700 | -0.1500 | -0.1900 | -0.1900 | -0.1300 | -0.1400 | -0.1300 | -0.0300 | -0.1100 | -0.0500 | -0.0700 | -0.0600 | -0.0700 |
| Dividend per Share | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Announcement Date | 28/03/22 | 16/05/22 | 15/08/22 | 14/11/22 | 30/03/23 | 15/05/23 | 14/08/23 | 14/11/23 | 01/04/24 | 14/05/24 | - | - | - |
1USD in Million2USD
Estimates
Balance Sheet Analysis
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|---|---|
| Net Debt | - | - | - | - | - | - | - | - |
| Net Cash position | - | - | - | - | - | - | - | - |
| Leverage (Debt/EBITDA) | - | - | - | - | - | - | - | - |
| Free Cash Flow | - | - | - | - | - | - | - | - |
| ROE (net income / shareholders' equity) | - | - | - | - | - | - | - | - |
| ROA (Net income/ Total Assets) | - | - | - | - | - | - | - | - |
| Assets 1 | - | - | - | - | - | - | - | - |
| Book Value Per Share | - | - | - | - | - | - | - | - |
| Cash Flow per Share | - | - | - | - | - | - | - | - |
| Capex | - | - | - | - | - | - | - | - |
| Capex / Sales | - | - | - | - | - | - | - | - |
| Announcement Date | 18/02/20 | 04/02/21 | 28/03/22 | 30/03/23 | 01/04/24 | - | - | - |
1USD in Million
Estimates
EPS & Dividend
Year-on-year evolution of the PER
Change in Enterprise Value/EBITDA
Sell
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.516
USD
Average target price
2.5
USD
Spread / Average Target
+384.50%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +34.40% | 50.85B | |
| +0.46% | 42.82B | |
| +49.62% | 42.03B | |
| -4.96% | 29.55B | |
| +10.96% | 26.11B | |
| -21.63% | 19.13B | |
| +8.36% | 13.05B | |
| +27.13% | 12.16B | |
| +24.48% | 12.08B |
- Stock Market
- Equities
- BCLI Stock
- GHDN Stock
- Financials Brainstorm Cell Therapeutics Inc.